MegaRobo Valuation, Funding & Investors

MegaRobo is valued at $1B as of June 2022.

Last MegaRobo valuation

$1B

Series C · Jun 2022

Last MegaRobo funding round

$300M

Series C · Jun 2022

Cumulative funding MegaRobo raised

$426M

across 5 funding rounds

Key investors in MegaRobo

  • Sinovation Ventures
  • Joy Capital
  • Matrix Partners China
  • Bosch Ventures
  • GGV Capital
  • Goldman Sachs Asset Management

MegaRobo Overview

About MegaRobo

MegaRobo is a Beijing-based robotics company, founded in 2016, that builds automation systems combining AI software, analytical instruments, laboratory hardware, and consumables for life-sciences research. Its technology targets applications such as new-drug R&D, genetic engineering, and clinical diagnostics, addressing talent shortages in laboratory work through automated testing and analysis. The company has grown to nearly 1,000 employees across offices in China, the UK, and the US, and has partnered with organizations including WuXi AppTec and Bosch.


Founded

2016

HQ

ChinaChina

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$1B (Jun 2022)

MegaRobo Valuation

MegaRobo is currently valued at $1B, based on its Series C in June 2022.

The $300M round was led by Asia Investment Capital, GGV Capital and Goldman Sachs Asset Management, with participation from Yumeng Capital, Taihecap, U-Member Capital, Harvest Capital Management, Sinovation Ventures and 2 other investors.

MegaRobo valuation by funding round

MegaRobo valuation by funding round
DateStageValuation
Jun 2022Series C$1B

MegaRobo Funding History

MegaRobo has raised a total of $426M across 5 funding rounds.

MegaRobo's first fundraising round was a $800K angel round in May 2016. The most recent completed round was a $300M Series C in June 2022.

MegaRobo funding rounds

MegaRobo funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jun 2022Series CAsia Investment Capital (lead); GGV Capital (lead); Goldman Sachs Asset Management (lead); Yumeng Capital; Taihecap; U-Member Capital; Harvest Capital Management; Sinovation Ventures; Redview Capital; Pavilion Capital$300M$1BMegaRobo Technologies, founded in 2016 in Beijing, China, develops robotic automation solutions integrating AI software, analytical instruments, laboratory hardware, and consumables for life sciences research, targeting challenges like talent shortages in new drug R&D, genetic engineering, and clinical diagnosis. The company operates offices and labs in Beijing, Suzhou, Shanghai, Shenzhen, the U.K., and the U.S., employing nearly 1,000 people with 60% in research roles. It serves sectors including stem cell therapy, genetics, and traditional Chinese medicine, with plans to expand production, R&D, new business lines, and global client services; roughly 10% of revenue was from overseas at the time, aiming for 50% by 2027. On June 15, 2022, MegaRobo closed a $300 million Series C funding round led by Asia Investment Capital, GGV Capital, and Goldman Sachs Asset Management, with participation from Sinovation Ventures, Pavilion Capital, Starr Capital, U-Member Capital, Redview Capital, Harvest Capital Management, Taihecap, and Yumeng Capital. This brought total funding to approximately $425.76 million across multiple rounds, following a Series B that raised $125 million. Sources estimate the post-money valuation exceeded $1 billion USD, achieving unicorn status. Proceeds from the round support increased R&D investment, production capacity expansion, and international market penetration, including a COVID-19 testing solution. Prior investors include Robert Bosch venture unit, WuXi AppTec, Matrix Partners China, and Joy Capital. The company has since been reported planning a Hong Kong IPO to raise at least $300 million, with backers like WuXi AppTec and Bosch.
May 2021Undisclosed stageWuxi AppTec (lead); Matrix Partners China; Joy Capital; Bosch Ventures; Starfield Food & Science Technology; Future Capital; Sinovation Ventures; Nice Tuan$65M-MegaRobo announced the completion of a US$65 million Series B financing round on May 28, 2021, led by WuXi AppTec with participation from Joy Capital, Sinovation Ventures, Matrix Partners China, Bosch Venture Capital, Future Capital, and Liando Investment. This brought the company's total raised to US$125 million since November 2020. The company is a robotics and artificial intelligence technology provider focused on intelligent automation solutions. MegaRobo used the financing to deepen research and development in intelligent automation, improve business capabilities, and strengthen its strategic partnership with WuXi AppTec on applications in life sciences and drug development. In April 2021, MegaRobo launched IntellVega, a technology platform integrating intelligent control, machine vision, and deep learning to create customizable AI algorithm libraries for industrial testing and life sciences applications. The company later pursued an initial public offering in Hong Kong, with reports from 2025 indicating a planned IPO targeting US$300 million in fundraising, having reached a US$1 billion valuation by 2022.
Feb 2021Series BMatrix Partners China (lead); Joy Capital; Sinovation Ventures$30M-MegaRobo is a Chinese company specializing in intelligent automation and robotics, particularly for applications in life sciences and laboratory research. It develops autonomous agents for robotics in sectors like new drug R&D, leveraging AI and robotics integration through its MegaLab initiative. The company has attracted top-tier strategic and financial investors since its Series A round led by Joy Capital. In May 2021, MegaRobo closed a new financing round of US$65 million led by WuXi AppTec, with participation from Joy Capital, Sinovation Ventures, Matrix Partners China, Bosch Venture Capital, Future Capital, and Liando Investment. This round followed previous financings, bringing total funding since November 2020 to US$125 million. Proceeds from the May 2021 round were allocated to deepen R&D in intelligent automation, enhance business capabilities, strengthen the strategic alliance with WuXi AppTec for new drug R&D applications, and expand MegaLab to explore robotics-AI synergies in life sciences. WuXi AppTec planned deeper cooperation on laboratory automation post-investment. Joy Capital, an early backer, highlighted MegaRobo's contributions to life sciences and COVID-19 efforts. MegaRobo later filed for a Hong Kong IPO, targeting over $1B public market valuation, with estimated 40% growth and a China TAM of $4.7B in 2024 growing to $19B by 2030.
Nov 2020Series BSinovation Ventures (lead); Joy Capital; Bosch Ventures; Liando Investment$30M-MegaRobo Technologies is a Beijing-based startup founded in 2016 that develops robotics and AI solutions for life sciences research, including automation for new drug R&D, genetic engineering, clinical diagnosis, stem cell therapy, genetics, and traditional Chinese medicine. The company also offers systems for light manufacturing, retail, and has a COVID-19 testing solution, employing around 1,000 people with 600 research professionals across offices in China, the U.K., and U.S. In November 2020 or around March 2020, MegaRobo raised $30 million in a Series B funding round, matching the investors Bosch Ventures (Robert Bosch venture unit), Joy Capital, and lead investor Sinovation Ventures, as part of its early funding history totaling over $150 million across seven prior rounds before Series C. This Series B round preceded further capital raises, including additional Series B tranches totaling about $125 million closed around mid-2022 and a $300 million Series C in June 2022 led by Goldman Sachs Asset Management, GGV Capital, and Asia Investment Capital, with participation from Sinovation Ventures and others like Pavilion Capital and Starr Capital. The Series C funding was used to boost R&D, expand production capacity, explore new business lines, and grow international sales, where roughly 10% of revenue was overseas at the time with plans to reach 50% by 2027. Sources estimate MegaRobo achieved unicorn status with over $1 billion valuation post-Series C. MegaRobo plans international expansion and advanced life sciences infrastructure. In 2025, it was reported planning a Hong Kong IPO to raise $300 million, referencing the prior $1 billion valuation from 2022.
May 2016Angel-$800K--

Who has invested in MegaRobo?

18 investors have backed MegaRobo across its funding rounds, including Sinovation Ventures, Joy Capital, Matrix Partners China, Bosch Ventures, GGV Capital and Goldman Sachs Asset Management.

Lead investors include Asia Investment Capital, GGV Capital, Goldman Sachs Asset Management, Wuxi AppTec, Matrix Partners China and 1 other investor.


MegaRobo Investors

Investors in MegaRobo by funding rounds participated
InvestorHQRoundsRoleFirst check
Sinovation VenturesChinaBeijing4LeadNov 2020
Joy CapitalChinaBeijing3ParticipantNov 2020
Matrix Partners ChinaChinaBeijing2LeadFeb 2021
Bosch VenturesGermanyGermany2ParticipantNov 2020
Wuxi AppTecChinaShanghai1LeadMay 2021
Yumeng Capital--1ParticipantJun 2022
TaihecapChinaBeijing1ParticipantJun 2022
Starfield Food & Science TechnologyChinaShenzhen1ParticipantMay 2021
Future CapitalGermanyFrankfurt1ParticipantMay 2021
U-Member Capital--1ParticipantJun 2022
Harvest Capital ManagementChinaBeijing1ParticipantJun 2022
Liando InvestmentUnited KingdomLondon1ParticipantNov 2020
GGV CapitalUnited StatesSan Francisco, CA1LeadJun 2022

This data is available for Pro users. Sign up to see all 18 MegaRobo investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Investments by MegaRobo

MegaRobo has invested in 2 companies to date.

Latest investment by MegaRobo was on October 23rd 2023. MegaRobo invested in ENSEM Therapeutics in their $10M Series A round.


Latest Investments by MegaRobo

ENSEM Therapeutics
OxCan
OxCan
Description
ENSEM Therapeutics is a biotechnology company utilizing the Kinetic Ensemble platform for small-molecule drug discovery in oncology. Based in San Diego, California, it targets undruggable proteins through fragment-based screening and AI-optimized kinetics. ENSEM advances candidates for solid tumors and plans expansion to genetic diseases, with partnerships in medicinal chemistry.
OxCan develops machine learning algorithms combined with liquid biopsy techniques for early detection of lung cancer. The platform analyzes circulating tumor DNA from blood samples to identify high-risk individuals before symptoms appear. Oxford University spinout, the company conducts clinical trials in the United Kingdom and partners with NHS trusts for validation studies. OxCan's assays achieve sensitivity above standard imaging methods in pilot data. It targets smokers and former smokers for screening programs in primary care settings.
OxCan develops machine learning algorithms combined with liquid biopsy techniques for early detection of lung cancer. The platform analyzes circulating tumor DNA from blood samples to identify high-risk individuals before symptoms appear. Oxford University spinout, the company conducts clinical trials in the United Kingdom and partners with NHS trusts for validation studies. OxCan's assays achieve sensitivity above standard imaging methods in pilot data. It targets smokers and former smokers for screening programs in primary care settings.
HQ CountryUnited StatesUnited KingdomUnited Kingdom
HQ City
Boston, MA
Oxford
Oxford
Deal Date23 Oct 202310 Jan 20236 Sep 2021
RoundSeries ASeedSeed
Raised$10M$4M$2M
InvestorsBoquan Capital; Legend StarEka Ventures; LifeArc; Oxford Technology ManagementCancer Research UK; Civilization Ventures; Brad Wilson; Oxford Technology Management; Marcus East; The Francis Crick Institute
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all MegaRobo investments and their VC round multiples.

Start Free Trial

MegaRobo Competitors

MegaRobo competitors include listed companies like UBtech Robotics and Cmes Robotics, and private ones like Cornerstone Robotics, Enveda Biosciences, Forterra and Gravis Robotics.

Public and private companies comparable to MegaRobo
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
UBtech RoboticsChinaChinaPublicly listed$298M($108M)$5.1B9.5x
Cmes RoboticsSouth KoreaSouth KoreaPublicly listed$10M($12M)$157M-
Cornerstone RoboticsHong KongHong KongPrivate--$1B-
Enveda BiosciencesUnited StatesBoulder, COPrivate--$1B-
ForterraUnited StatesWashington, DCPrivate-$82M$1B-
Gravis RoboticsSwitzerlandZurichPrivate--$1B-

MegaRobo Public Comps

MegaRobo is still privately-owned, but its public comps include SEER Robotics, Extreme Vision, iFLYHealth, ODDITY Tech, AEVEX, Braiin, ZoomInfo, Xtend AI Robotics, Beijing Haitian Ruisheng and Kodiak AI.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SEER Robotics$66M($6M)13.2x-(156.2x)-
Extreme Vision$44M($6M)22.8x11.6x(163.7x)-
iFLYHealth$136M($7M)7.7x6.2x(150.8x)(144172.5x)
ODDITY Tech$810M$131M1.5x1.8x9.6x18.3x
AEVEX$433M$30M5.2x3.5x74.9x25.6x
Braiin$73M($15M)15.8x13.0x(76.1x)89.6x
ZoomInfo$1.2B$326M2.0x2.1x7.8x5.1x
Xtend AI Robotics$20M($27M)64.2x-(47.5x)-

This data is available for Pro users. Sign up to see all MegaRobo competitors and their valuation data.

Start Free Trial

Common questions about MegaRobo

When was MegaRobo founded?MegaRobo was founded in 2016.
Where is MegaRobo headquartered?MegaRobo is headquartered in China.
Is MegaRobo publicly listed?No, MegaRobo is a private, VC-backed company.
What is MegaRobo's valuation?MegaRobo was last valued at $1B in its Series C in June 2022.
How much funding has MegaRobo raised?MegaRobo has raised $426M across 5 funding rounds.
What was MegaRobo's last funding round?MegaRobo's last funding round was a $300M Series C in June 2022, led by Asia Investment Capital, GGV Capital and Goldman Sachs Asset Management.
Who are MegaRobo's investors?MegaRobo's investors include Sinovation Ventures, Joy Capital, Matrix Partners China, Bosch Ventures, Wuxi AppTec, Yumeng Capital, Taihecap, Starfield Food & Science Technology, Future Capital, U-Member Capital and 8 others.
Which companies are comparable to MegaRobo?Companies comparable to MegaRobo include UBtech Robotics, Cmes Robotics, Cornerstone Robotics, Enveda Biosciences, Forterra and Gravis Robotics.
How many companies has MegaRobo invested in?MegaRobo has invested in 2 companies, including ENSEM Therapeutics and OxCan.
What was MegaRobo's last investment?In October 2023, MegaRobo invested in ENSEM Therapeutics' $10M Series A alongside Boquan Capital and Legend Star.

See companies similar to MegaRobo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial